call on doc glp-1 Micro-dosing vs full-dose GLP-1… which approach is right for you? Not everyone needs the same path. Some bodies respond better to a slower, lower-dose approach focused tolerance and consistency. Others may Microdosing GLP-1 Therapy in Ventura

CagriSema Clinical Trials Evidence CagriSema's evidence base is unusually strong for a peptide research stack: two large Phase 3 trials with NEJM publications, plus Phase 1b/2 supporting data

Lancet (2025)

Cell Reports, 21, 27242736

Acidic or alkaline reconstitution solutions may provide antimicrobial benefits but can accelerate peptide breakdown

and (7) case reports or studies with fewer than 3 procedures

(NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management